{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T09:11:00Z","timestamp":1771233060725,"version":"3.50.1"},"reference-count":5,"publisher":"Oxford University Press (OUP)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1093\/ageing\/afx073","type":"journal-article","created":{"date-parts":[[2017,4,11]],"date-time":"2017-04-11T07:29:30Z","timestamp":1491895770000},"page":"870-871","source":"Crossref","is-referenced-by-count":15,"title":["Rivaroxaban withdrawal and rebound hypercoagulability leading to upper extremity deep vein thrombosis: a case report"],"prefix":"10.1093","volume":"46","author":[{"given":"Subramaniam","family":"Nagasayi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Surendra","family":"Varman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yeo Yan","family":"Ting","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy","family":"Ang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2017,5,3]]},"reference":[{"key":"key\n\t\t\t\t20170830112815_afx073C1","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMcp1008740","article-title":"Clinical practice. Deep-vein thrombosis of the upper extremities","volume":"364","year":"2011","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170830112815_afx073C2","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.jacc.2012.09.057","article-title":"Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation)","volume":"61","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20170830112815_afx073C3","doi-asserted-by":"crossref","first-page":"116.e3","DOI":"10.1016\/j.ajem.2015.05.030","article-title":"Left atrial thrombus formation after brief interruption of rivaroxaban","volume":"34","year":"2016","journal-title":"Am J Emerg Med"},{"key":"key\n\t\t\t\t20170830112815_afx073C4","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ijcard.2016.03.148","article-title":"Rebound thrombosis within 24 hours after interruption of therapy with rivaroxaban","volume":"212","year":"2016","journal-title":"Int J Cardiol"},{"key":"key\n\t\t\t\t20170830112815_afx073C5","first-page":"207","article-title":"Rivaroxaban rebound acute coronary event: a post marketing experience","volume":"4","year":"2013","journal-title":"Cardiol Res"}],"container-title":["Age and Ageing"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ageing\/article-pdf\/46\/5\/870\/19650586\/afx073.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,30]],"date-time":"2017-08-30T11:28:20Z","timestamp":1504092500000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/ageing\/article\/46\/5\/870\/3791763\/Rivaroxaban-withdrawal-and-rebound"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,3]]},"references-count":5,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2017,5,3]]},"published-print":{"date-parts":[[2017,9]]}},"URL":"https:\/\/doi.org\/10.1093\/ageing\/afx073","relation":{},"ISSN":["0002-0729","1468-2834"],"issn-type":[{"value":"0002-0729","type":"print"},{"value":"1468-2834","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,3]]}}}